Desmond J Fitzgerald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11368962/publications.pdf

Version: 2024-02-01

38	5,138	236925	330143
papers	citations	25 h-index	37 g-index

38	38	38	4616
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lack of Bioequivalence Among Lowâ€dose, Entericâ€coated Aspirin Preparations. Clinical Pharmacology and Therapeutics, 2018, 103, 1047-1051.	4.7	9
2	Historical Lessons in Translational Medicine. Circulation Research, 2013, 112, 174-194.	4.5	38
3	Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood, 2010, 116, 4646-4656.	1.4	90
4	Canonical Wnt signaling negatively regulates platelet function. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19836-19841.	7.1	61
5	Contribution of cyclooxygenase-1 to thromboxane formation, plateletâ€“vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis, 2009, 202, 84-91.	0.8	46
6	Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial). American Journal of Cardiology, 2008, 102, 1285-1290.	1.6	12
7	Isolation of the Platelet Releasate. , 2007, 357, 307-312.		12
8	Aspirin and Clopidogrel Resistance. Hematology American Society of Hematology Education Program, 2007, 2007, 114-120.	2.5	38
9	Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target. Current Pharmaceutical Design, 2007, 13, 2656-2661.	1.9	16
10	Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Circulation, 2007, 115, 2196-2207.	1.6	191
11	Moderation of the platelet releasate response by aspirin. Blood, 2007, 109, 4786-4792.	1.4	120
12	Drug Insight: aspirin resistanceâ€”fact or fashion?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, E1-E1.	3.3	4
13	Aspirin Resistance and Atherothrombotic Disease. Journal of the American College of Cardiology, 2006, 48, 846-847.	2.8	2
14	Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. European Heart Journal, 2006, 27, 1251-1256.	2.2	33
15	Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H532-H536.	3.2	18
16	Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke, 2006, 37, 2153-2158.	2.0	206
17	Correlation of probioticLactobacillus salivariusgrowth phase with its cell wall-associated proteome. FEMS Microbiology Letters, 2005, 252, 153-159.	1.8	50
18	Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. Journal of the American College of Cardiology, 2005, 46, 1258-1263.	2.8	205

#	Article	IF	Citations
19	Aspirin and coronary artery disease. Thrombosis and Haemostasis, 2004, 92, 1175-1181.	3.4	60
20	Intravascular Thrombosis After Hypoxia-Induced Pulmonary Hypertension. Circulation, 2004, 110, 2701-2707.	1.6	92
21	Application of Proteomics to the Study of Platelet Regulatory Mechanisms. Trends in Cardiovascular Medicine, 2004, 14, 207-220.	4.9	18
22	Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clinical Pharmacology and Therapeutics, 2004, 75, 60-69.	4.7	14
23	Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood, 2004, 103, 2096-2104.	1.4	725
24	Optimal suppression of thromboxane a2formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. Journal of the American College of Cardiology, 2004, 43, 526-531.	2.8	30
25	Induction of cyclooxygenaseâ€1 and â€2 modulates angiogenic responses to engagement of Î±_vÎ²₃. British Journal of Haematology, 2003, 121, 157-164.	2.5	34
26	Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis. Circulation, 2003, 108, 3017-3023.	1.6	129
27	Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes: Where Are We Now?. Seminars in Vascular Medicine, 2003, 03, 385-390.	2.1	7
28	Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics, 2002, 2, 642-648.	2.2	165
29	A Val193Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. British Journal of Haematology, 2001, 115, 131-139.	2.5	11
30	Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)â€dependent proliferation of endothelial cells (EC) via the VEGFâ€2 receptor. FASEB Journal, 2001, 15, 1667-1669.	0.5	64
31	Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. Journal of Clinical Investigation, 2001, 108, 585-590.	8.2	171
32	Cyclooxygenase-1 and -2â€“Dependent Prostacyclin Formation in Patients With Atherosclerosis. Circulation, 2000, 102, 840-845.	1.6	368
33	Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. Journal of the American College of Cardiology, 2000, 36, 1514-1519.	2.8	135
34	Oxidative Damage of Cardiomyocytes Is Limited by Extracellular Regulated Kinases 1/2-mediated Induction of Cyclooxygenase-2. Journal of Biological Chemistry, 1999, 274, 5038-5046.	3.4	336
35	Ticlopidine and Clopidogrel. Circulation, 1999, 100, 1667-1672.	1.6	461
36	Reduced fetal exposure to aspirin using a novel controlled-release preparation in normotensive and hypertensive pregnancies. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 732-738.	2.3	12

#	Article	IF	Citations
37	Platelet activation in the pathogenesis of unstable angina: Importance in determining the response to plasminogen activators. American Journal of Cardiology, 1991, 68, B51-B57.	1.6	17
38	Platelet Activation in Unstable Coronary Disease. New England Journal of Medicine, 1986, 315, 983-989.	27.0	1,138